Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared on X:
“Hot off the press in JAMAOnc – When TNM Staging Is Not Sufficient.
With Chadi Nabhan I argue that after 7 decades of remarkable service, anatomic staging alone can no longer carry the weight we place on it torial on why and what we propose.
Title: When TNM Staging Is Not Sufficient
Authors: Vivek Subbiah, Chadi Nabhan
Read the Full Article.
Drew Moghanaki, Lung Cancer Specialist and Endowed Thoracic Oncology Research Chair at UCLA and Co-Director of the Lung Precision Oncology Program at VA Greater Los Angeles, shared a post by Vivek Subbiah, adding:
“I fully believe it’s time to expand TNM to something like TNM-DB. It would open up greater consideration of prognostic factors that matter, such as NGS and MRD results. Until we expand, they will continue to be deemed speculative when they might be more crucial than a group stage.”
Other articles featuring Vivek Subbiah on OncoDaily.